Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., July 13…
Read the full articleYou might also wanna read
Xi to present China's AI dream at major conference
Manila Times·1h ago
Ohmyhome Ltd Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Manila Times·1h ago
Pele's World Cup jersey fetches $4.9 million at US auction
Manila Times·1h ago
Cycurion Receives Nasdaq Delisting Determination Letter; Appeal Underway, Trading to Continue, Focus on Shareholder Value
Manila Times·1h ago
Capstone Infrastructure Corporation Reports Results of Exercise of Conversion Rights for Cumulative 5-Year Rate Reset Preferred Shares, Series A
Manila Times·1h ago
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
Manila Times·1h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.